{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T01:33:56Z","timestamp":1792460036596,"version":"4.5.0"},"reference-count":46,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2022,7,22]],"date-time":"2022-07-22T00:00:00Z","timestamp":1658448000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,7,22]],"date-time":"2022-07-22T00:00:00Z","timestamp":1658448000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Alma Mater Studiorum - Universit\u00e0 di Bologna"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Exp Metastasis"],"published-print":{"date-parts":[[2022,10]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>The main treatment of MM metastases are systemic therapies, surgery, limb perfusion, and intralesional talimogene laherparepvec. Electrochemotherapy (ECT) is potentially useful also due to the high response rates recorded in cancers of any histology. No randomized studies comparing ECT with other local therapies have been published on this topic. We analyzed the available evidence on efficacy and toxicity of ECT in this setting.\u00a0PubMed, Scopus, and Cochrane databases were screened for paper about ECT on MM skin metastases. Data about tumor response, mainly in terms of overall response rate (ORR), toxicity (both for ECT alone and in combination with systemic treatments), local control (LC), and overall survival (OS) were collected. The methodological quality was assessed using a 20-item validated quality appraisal tool for case series.\u00a0Overall, 18 studies were included in our analysis. In studies reporting \u201cper patient\u201d tumor response the pooled complete response (CR) was 35.7% (95%CI 26.0\u201346.0%), and the pooled ORR was 80.6% (95%CI 68.7\u201390.1%). Regarding \u201cper lesion\u201d response, the pooled CR was 53.5% (95%CI 42.1\u201364.7%) and the pooled ORR was 77.0% (95%CI 56.0\u201392.6%). One-year LC rate was 80%, and 1-year OS was 67\u201386.2%. Pain (24.2\u201392.0%) and erythema (16.6\u201342.0%) were the most frequent toxicities. Two studies reported 29.2% and 41.6% incidence of necrosis.\u00a0ECT is effective in terms of tumor response and tolerated in patients with skin metastases from MM, albeit with a wide variability of reported results. Therefore, prospective trials in this setting are warranted.<\/jats:p>","DOI":"10.1007\/s10585-022-10180-9","type":"journal-article","created":{"date-parts":[[2022,7,22]],"date-time":"2022-07-22T17:09:41Z","timestamp":1658509781000},"page":"743-755","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":19,"title":["Electrochemotherapy of skin metastases from malignant melanoma: a PRISMA-compliant systematic review"],"prefix":"10.1007","volume":"39","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8012-4510","authenticated-orcid":false,"given":"Martina","family":"Ferioli","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valentina","family":"Lancellotta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna Myriam","family":"Perrone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandra","family":"Arcelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Galuppi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lidia","family":"Strigari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Milly","family":"Buwenge","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesca","family":"De Terlizzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silvia","family":"Cammelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberto","family":"Iezzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pierandrea","family":"De Iaco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luca","family":"Tagliaferri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessio G.","family":"Morganti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,7,22]]},"reference":[{"key":"10180_CR1","unstructured":"GLOBOCAN (2020) Cancer Incidence and Mortality Worldwide: IARC CancerBase. Lyon, France: International Agency for Research on Cancer; http:\/\/globocan.iarc.fr. Accessed on 13 Sept\u00a02021"},{"issue":"5","key":"10180_CR2","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1097\/CMR.0b013e32832ac775","volume":"19","author":"P Savoia","year":"2009","unstructured":"Savoia P, Fava P, Nard\u00f2 T, Osella-Abate S, Quaglino P, Bernengo MG (2009) Skin metastases of malignant melanoma: a clinical and prognostic survey. Melanoma Res 19(5):321\u2013326","journal-title":"Melanoma Res"},{"issue":"8","key":"10180_CR3","doi-asserted-by":"publisher","first-page":"865","DOI":"10.1111\/ijd.14314","volume":"58","author":"CA Goggins","year":"2019","unstructured":"Goggins CA, Khachemoune A (2019) The use of electrochemotherapy in combination with immunotherapy in the treatment of metastatic melanoma: a focused review. Int J Dermatol 58(8):865\u2013870","journal-title":"Int J Dermatol"},{"key":"10180_CR4","unstructured":"NCCNguidelines (2021)\u00a0\u00a0https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/cutaneous_melanoma.pdf. Accessed 13"},{"issue":"7","key":"10180_CR5","doi-asserted-by":"publisher","first-page":"874","DOI":"10.1080\/0284186X.2018.1454602","volume":"57","author":"J Gehl","year":"2018","unstructured":"Gehl J, Sersa G, Matthiessen LW, Muir T, Soden D, Occhini A, Quaglino P, Curatolo P, Campana LG, Kunte C, Clover AJP, Bertino G, Farricha V, Odili J, Dahlstrom K, Benazzo M, Mir LM (2018) Updated standard operating procedures for electrochemotherapy of cutaneous tumours and skin metastases. Acta Oncol 57(7):874\u2013882","journal-title":"Acta Oncol"},{"issue":"11","key":"10180_CR6","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/j.ejcsup.2006.08.002","volume":"4","author":"M Marty","year":"2006","unstructured":"Marty M, Sersa G, Garbay JR, Gehl J, Collins CG, Snoj M et al (2006) Electrochemotherapy\u2014an easy, highly effective and safe treatment of cutaneous and subcutaneous metastases: results of ESOPE (European Standard Operating Procedures of Electrochemotherapy) study. Eur J Cancer Suppl 4(11):3\u201313","journal-title":"Eur J Cancer Suppl"},{"issue":"12","key":"10180_CR7","doi-asserted-by":"publisher","first-page":"2257","DOI":"10.1016\/j.ejso.2019.07.003","volume":"45","author":"J Morley","year":"2019","unstructured":"Morley J, Grocott P, Purssell E, Murrells T (2019) Electrochemotherapy for the palliative management of cutaneous metastases: a systematic review and meta-analysis. Eur J Surg Oncol 45(12):2257\u20132267","journal-title":"Eur J Surg Oncol"},{"issue":"5","key":"10180_CR8","doi-asserted-by":"publisher","first-page":"729","DOI":"10.1586\/era.10.43","volume":"Ther10","author":"T Jarm","year":"2010","unstructured":"Jarm T, Cemazar M, Miklavcic D, Sersa G (2010) Antivascular effects of electrochemotherapy: implications in treatment of bleeding metastases. Expert Rev Anticancer Ther10(5):729\u2013746","journal-title":"Expert Rev Anticancer"},{"issue":"4","key":"10180_CR9","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3892\/mco.2021.2226","volume":"14","author":"M Ferioli","year":"2021","unstructured":"Ferioli M, Galuppi A, Buwenge M, Cammelli S, Perrone AM, Macchia G, Deodato F, Cilla S, Zamagni A, De Terlizzi F, Tagliaferri L, De Iaco P, Morganti AG (2021) Electrochemotherapy in Kaposi sarcoma: a systematic review. Mol Clin Oncol 14(4):1\u20135","journal-title":"Mol Clin Oncol"},{"issue":"1","key":"10180_CR10","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s10585-020-10063-x","volume":"38","author":"M Ferioli","year":"2021","unstructured":"Ferioli M, Perrone AM, Buwenge M, Arcelli A, Zamagni A, Macchia G, Deodato F, Cilla S, Tagliaferri L, De Terlizzi F, De Iaco P, Zamagni C, Morganti AG (2021) Electrochemotherapy of skin metastases from breast cancer: a systematic review. Clin Exp Metastasis 38(1):1\u201310. doi: https:\/\/doi.org\/10.1007\/s10585-020-10063-x","journal-title":"Clin Exp Metastasis"},{"issue":"3","key":"10180_CR11","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1111\/dth.12098","volume":"27","author":"F Ricotti","year":"2014","unstructured":"Ricotti F, Giuliodori K, Cataldi I, Campanati A, Ganzetti G, Ricotti G, Offidani A (2014) Electrochemotherapy: an effective local treatment of cutaneous and subcutaneous melanoma metastases. Dermatol Ther 27(3):148\u2013152. doi: https:\/\/doi.org\/10.1111\/dth.12098","journal-title":"Dermatol Ther"},{"issue":"6","key":"10180_CR12","doi-asserted-by":"publisher","first-page":"821","DOI":"10.1002\/bjs.8749","volume":"99","author":"LG Campana","year":"2012","unstructured":"Campana LG, Valpione S, Mocellin S, Sundararajan R, Granziera E, Sartore L, Chiarion-Sileni V, Rossi CR (2012) Electrochemotherapy for disseminated superficial metastases from malignant melanoma. Br J Surg 99(6):821\u2013830. doi: https:\/\/doi.org\/10.1002\/bjs.8749","journal-title":"Br J Surg"},{"key":"10180_CR13","unstructured":"PROSPERO database. https:\/\/www.crd.york.ac.uk\/prospero\/. Accessed 4 Jan\u00a02021"},{"key":"10180_CR14","doi-asserted-by":"crossref","unstructured":"Moher D, Liberati A, Tetzlaff J, Altman DG (2009) Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med 6(7)","DOI":"10.1371\/journal.pmed.1000097"},{"key":"10180_CR15","unstructured":"Moga C, Guo B, Schopflocher D, Harstall C (2012) Development of a quality appraisal tool for case series studies using a modified Delphi technique. Edmonton: Institute of Health Economics; http:\/\/www.ihe.ca\/advanced-search\/development-of-a-quality-appraisal-tool-for-case-series-studies-using-a-modified-delphi-technique. Accessed 13 Sept\u00a02021"},{"key":"10180_CR16","first-page":"229","volume":"29","author":"Z Rudolf","year":"1995","unstructured":"Rudolf Z, Stabuc B, Cemazar M, Miklavcic D, Vodovnik L, Seda G et al (1995) Electrochemotherapy with bleomycin. The first clinical experience in malignant melanoma patients. Radial Oneal 29:229\u2013264","journal-title":"Radial Oneal"},{"issue":"11","key":"10180_CR17","doi-asserted-by":"publisher","first-page":"1353","DOI":"10.1001\/archderm.1996.03890350095015","volume":"132","author":"LF Glass","year":"1996","unstructured":"Glass LF, Pepine ML, Fenske NA, Jaroszeski M, Reintgen DS, Heller R (1996) Bleomycin-mediated electrochemotherapy of metastatic melanoma. AMA Arch Derm 132(11):1353\u20131357","journal-title":"AMA Arch Derm"},{"issue":"5","key":"10180_CR18","doi-asserted-by":"publisher","first-page":"468","DOI":"10.1097\/00008390-200010000-00009","volume":"10","author":"MP Rols","year":"2000","unstructured":"Rols MP, Bachaud JM, Giraud P, Chevreau C, Roch\u00e9 H, Teissi\u00e9 J (2000) Electrochemotherapy of cutaneous metastases in malignant melanoma. Melanoma Res 10(5):468\u2013474","journal-title":"Melanoma Res"},{"issue":"2","key":"10180_CR19","doi-asserted-by":"publisher","first-page":"127","DOI":"10.2217\/mmt.15.9","volume":"2","author":"C Carac\u00f2","year":"2015","unstructured":"Carac\u00f2 C, Marone U, Simeone E, Grimaldi AM, Botti G, Del Giudice M, Ascierto PA, Mozzillo N (2015) Electrochemotherapy in melanoma patients: a single institution experience. Melanoma Manag 2(2):127\u2013132","journal-title":"Melanoma Manag"},{"issue":"6","key":"10180_CR20","doi-asserted-by":"publisher","first-page":"e1008842","DOI":"10.1080\/2162402X.2015.1008842","volume":"4","author":"N Mozzillo","year":"2015","unstructured":"Mozzillo N, Simeone E, Benedetto L, Curvietto M, Giannarelli D, Gentilcore G, Camerlingo R, Capone M, Madonna G, Festino L, Carac\u00f2 C, Di Monta G, Marone U, Di Marzo M, Grimaldi AM, Mori S, Ciliberto G, Ascierto PA (2015) Assessing a novel immuno-oncology-based combination therapy: ipilimumab plus electrochemotherapy. Oncoimmunology 4(6):e1008842","journal-title":"Oncoimmunology"},{"issue":"1","key":"10180_CR21","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1515\/raon-2015-0048","volume":"16","author":"A Hribernik","year":"2016","unstructured":"Hribernik A, Cemazar M, Sersa G, Bosnjak M, Snoj M (2016) Effectiveness of electrochemotherapy after IFN-\u03b1 adjuvant therapy of melanoma patients. Radiol Oncol 16(1):21\u201327. https:\/\/doi.org\/10.1515\/raon-2015-0048","journal-title":"Radiol Oncol"},{"issue":"8","key":"10180_CR22","doi-asserted-by":"publisher","first-page":"951","DOI":"10.1007\/s00262-016-1856-z","volume":"65","author":"M Heppt","year":"2016","unstructured":"Heppt M, Eigentler TK, K\u00e4hler KC, Herbst RA, G\u00f6ppner D, Gambichler T et al (2016) Immune checkpoint blockade with concurrent electrochemotherapy in advanced melanoma: a retrospective multicenter analysis. Cancer Immunol Immunother 65(8):951\u2013959. https:\/\/doi.org\/10.1007\/s00262-016-1856-z","journal-title":"Cancer Immunol Immunother"},{"issue":"3","key":"10180_CR23","first-page":"863","volume":"6","author":"G Sersa","year":"2000","unstructured":"Sersa G, Stabuc B, Cemazar M, Miklavcic D, Rudolf Z (2000) Electrochemotherapy with cisplatin: clinical experience in malignant melanoma patients. Clin Cancer Res 6(3):863\u2013867","journal-title":"Clin Cancer Res"},{"issue":"4","key":"10180_CR24","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1097\/00008390-200008000-00010","volume":"10","author":"G Ser\u0161a","year":"2000","unstructured":"Ser\u0161a G, \u0160tabuc B, \u010cema\u017ear M, Miklav\u010di\u010d D, Rudolf Z (2000) Electrochemotherapy with cisplatin: The systemic antitumour effectiveness of cisplatin can be potentiated locally by the application of electric pulses in the treatment of malignant melanoma skin metastases. Melanoma Res 10(4):381\u2013385","journal-title":"Melanoma Res"},{"issue":"1","key":"10180_CR25","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1097\/00008390-200502000-00008","volume":"15","author":"CM Byrne","year":"2005","unstructured":"Byrne CM, Thompson JF, Johnston H, Hersey P, Quinn MJ, Michael Hughes T, McCarthy WH (2005) Treatment of metastatic melanoma using electroporation therapy with bleomycin (electrochemotherapy). Melanoma Res 15(1):45\u201351","journal-title":"Melanoma Res"},{"issue":"3","key":"10180_CR26","doi-asserted-by":"publisher","first-page":"115","DOI":"10.2310\/7750.2006.00037","volume":"10","author":"C Gaudy","year":"2006","unstructured":"Gaudy C, Richard MA, Folchetti G, Bonerandi JJ, Grob JJ (2006) Randomized controlled study of electrochemotherapy in the local treatment of skin metastases of melanoma. J Cutan Med Surg 10(3):115\u2013121. https:\/\/doi.org\/10.2310\/7750.2006.00037","journal-title":"J Cutan Med Surg"},{"issue":"8","key":"10180_CR27","doi-asserted-by":"publisher","first-page":"2215","DOI":"10.1245\/s10434-008-9976-0","volume":"15","author":"P Quaglino","year":"2008","unstructured":"Quaglino P, Mortera C, Osella-Abate S, Barberis M, Illengo M, Rissone M et al (2008) Electrochemotherapy with intravenous bleomycin in the local treatment of skin melanoma metastases. Ann of Surg Oncol 15(8):2215\u20132222","journal-title":"Ann of Surg Oncol"},{"issue":"6","key":"10180_CR28","first-page":"816","volume":"37","author":"E Kis","year":"2011","unstructured":"Kis E, Ol\u00e1h J, \u00d3csai H, Baltas E, Gyulai R, Kem\u00e9ny L et al (2011) Electrochemotherapy of cutaneous metastases of melanoma\u2014a case series study and systematic review of the evidence. Dermatol Surg 37(6):816\u2013824","journal-title":"Dermatol Surg"},{"issue":"5","key":"10180_CR29","first-page":"499","volume":"151","author":"GM Tomassini","year":"2016","unstructured":"Tomassini GM, Covareli P, Tomassini MA, Corsi A, Bianchi L, Hansel K et al (2016) Electrochemotherapy with intravenous bleomycin for advanced non-melanoma skin cancers and for cutaneous and subcutaneous metastases from melanoma. G Ital Dermatol Venereol 151(5):499\u2013506","journal-title":"G Ital Dermatol Venereol"},{"issue":"6","key":"10180_CR30","doi-asserted-by":"publisher","first-page":"1475","DOI":"10.1111\/bjd.15340","volume":"176","author":"C Kunte","year":"2017","unstructured":"Kunte C, Letul\u00e9 V, Gehl J, Dahlstroem K, Curatolo P, Rotunno R, Muir T, Occhini A, Bertino G, Powell B, Saxinger W, Lechner G, Liew SH, Pritchard-Jones R, Rutkowski P, Zdzienicki M, Mowatt D, Sykes AJ, Orlando A, Mitsala G, Rossi CR, Campana L, Brizio M, de Terlizzi F, Quaglino P, Odili J (2017) InspECT (the International Network for Electrochemotherapy in the treatment of metastatic malignant melanoma: a prospective cohort study by InspECT. Br J Dermatol 176(6):1475\u201385","journal-title":"Br J Dermatol"},{"issue":"4","key":"10180_CR31","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1016\/j.ad.2014.10.007","volume":"106","author":"JM Mir-Bonaf\u00e9","year":"2015","unstructured":"Mir-Bonaf\u00e9 JM, Vilalta A, Alarc\u00f3n I, Carrera C, Puig S, Malvehy J, Rull R, Benn\u00e0ssar A (2015) Electrochemotherapy in the treatment of melanoma skin metastases: a report on 31 cases. Actas Dermosifiliogr 106(4):285\u2013291. doi: https:\/\/doi.org\/10.1016\/j.ad.2014.10.007","journal-title":"Actas Dermosifiliogr"},{"issue":"2","key":"10180_CR32","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1016\/j.ad.2016.08.008","volume":"108","author":"MJ Aguado-Romeo","year":"2017","unstructured":"Aguado-Romeo MJ, Benot-L\u00f3pez S, Romero-Tabares A (2017) Electrochemotherapy for the treatment of unresectable locoregionally advanced cutaneous melanoma: a systematic review. Actas Dermosifiliogr 108(2):91\u201397","journal-title":"Actas Dermosifiliogr"},{"key":"10180_CR33","doi-asserted-by":"crossref","unstructured":"Clover AJP, de Terlizzi F, Bertino G, Curatolo P, Odili J, Campana LG, Kunte C, Muir T, Brizio M, Sersa G, Pritchard Jones R, Moir G, Orlando A, Banerjee SM, Kis E, McCaul JA, Grischke EM, Matteucci P, Mowatt D, Bechara FG, Mascherini M, Lico V, Giorgione R, Seccia V, Schepler H, Pecorari G, MacKenzie Ross AD, Bisase B, Gehl J (2020) Electrochemotherapy in the treatment of cutaneous malignancy: outcomes and subgroup analysis from the cumulative results from the pan-European International Network for Sharing Practice in Electrochemotherapy database for 2482 lesions in 987 patients (2008\u20132019). Eur J Cancer 138:30\u201340","DOI":"10.1016\/j.ejca.2020.06.020"},{"key":"10180_CR34","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1016\/j.bioelechem.2017.09.009","volume":"119","author":"K Ursic","year":"2018","unstructured":"Ursic K, Kos S, Kamensek U, Cemazar M, Scancar J, Bucek S, Kranjc S, Staresinic B, Sersa G (2018) Comparable effectiveness and immunomodulatory actions of oxaliplatin and cisplatin in electrochemotherapy of murine melanoma. Bioelectrochemistry 119:161\u2013171","journal-title":"Bioelectrochemistry"},{"issue":"9","key":"10180_CR35","doi-asserted-by":"publisher","first-page":"1291","DOI":"10.1007\/s00262-008-0462-0","volume":"57","author":"S Roux","year":"2008","unstructured":"Roux S, Bernat C, Al-Sakere B, Ghiringhelli F, Opolon P, Carpentier AF, Zitvogel L, Mir LM, Robert C (2008) Tumor destruction using electrochemotherapy followed by CpG oligodeoxynucleotide injection induces distant tumor responses. Cancer Immunol Immunother 57(9):1291\u20131300","journal-title":"Cancer Immunol Immunother"},{"issue":"9","key":"10180_CR36","doi-asserted-by":"publisher","first-page":"744","DOI":"10.1158\/2326-6066.CIR-15-0156","volume":"4","author":"S Theurich","year":"2016","unstructured":"Theurich S, Rothschild SI, Hoffmann M, Fabri M, Sommer A, Garcia-Marquez M, Thelen M, Schill C, Merki R, Schmid T, Koeberle D, Zippelius A, Baues C, Mauch C, Tigges C, Kreuter A, Borggrefe J, von Bergwelt-Baildon M, Schlaak M (2016) Local tumor treatment in combination with systemic ipilimumab immunotherapy prolongs overall survival in patients with advanced malignant melanoma. Cancer Immunol Res 4(9):744\u2013754","journal-title":"Cancer Immunol Res"},{"issue":"17","key":"10180_CR37","doi-asserted-by":"publisher","first-page":"25","DOI":"10.3390\/cancers13174289","volume":"13","author":"LG Campana","year":"2021","unstructured":"Campana LG, Peric B, Mascherini M, Spina R, Kunte C, Kis E et al (2021) Combination of pembrolizumab with electrochemotherapy in cutaneous metastases from melanoma: a comparative retrospective study from the InspECT and Slovenian Cancer Registry. Cancers (Basel) 13(17):25. doi: https:\/\/doi.org\/10.3390\/cancers13174289","journal-title":"Cancers (Basel)"},{"key":"10180_CR38","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1007\/978-3-319-22539-5_8","volume":"167","author":"MA Wilson","year":"2016","unstructured":"Wilson MA, Schuchter LM (2016) Chemotherapy for Melanoma. Cancer Treat Res 167:209\u2013229","journal-title":"Cancer Treat Res"},{"issue":"34","key":"10180_CR39","doi-asserted-by":"publisher","first-page":"5763","DOI":"10.1200\/JCO.2009.24.3675","volume":"27","author":"NN Senzer","year":"2009","unstructured":"Senzer NN, Kaufman HL, Amatruda T, Nemunaitis M, Reid T, Daniels G et al (2009) Phase II clinical trial of a granulocyte-macrophage colony-stimulating factor\u2013encoding, second-generation oncolytic herpesvirus in patients with unresectable metastatic melanoma. J Clin Oncol 27(34):5763\u20135771.\u00a0\u00a0https:\/\/doi.org\/10.1200\/JCO.2009.24.3675","journal-title":"J Clin Oncol"},{"key":"10180_CR40","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1186\/s40425-019-0623-z","volume":"7","author":"RHI Andtbacka","year":"2019","unstructured":"Andtbacka RHI, Collichio F, Harrington KJ, Middleton MR, Downey G, \u00d6hrling K et al (2019) Final analyses of OPTiM: a randomized phase III trial of talimogene laherparepvec versus granulocyte-macrophage colony-stimulating factor in unresectable stage III\u2013IV melanoma. J Immunother Cancer 7:145. https:\/\/doi.org\/10.1186\/s40425-019-0623-z","journal-title":"J Immunother Cancer"},{"key":"10180_CR41","doi-asserted-by":"publisher","first-page":"644","DOI":"10.1016\/j.jamcollsurg.2018.12.027","volume":"228","author":"RJ Louie","year":"2019","unstructured":"Louie RJ, Perez MC, Jajja MR, Sun J, Collichio F, Delman KA et al (2019) J Am Coll Surg 228:644\u2013649. https:\/\/doi.org\/10.1016\/j.jamcollsurg.2018.12.027","journal-title":"J Am Coll Surg"},{"issue":"8","key":"10180_CR42","doi-asserted-by":"publisher","first-page":"2174","DOI":"10.1093\/annonc\/mdt161","volume":"24","author":"JD Wolchok","year":"2013","unstructured":"Wolchok JD, Weber JS, Maio M, Neyns B, Harmankaya K, Chin K et al (2013) Four-year survival rates for patients with metastatic melanoma who received ipilimumab in phase II clinical trials. Ann of Oncol 24(8):2174\u20132180","journal-title":"Ann of Oncol"},{"issue":"10","key":"10180_CR43","doi-asserted-by":"publisher","first-page":"1191","DOI":"10.1200\/JCO.2014.56.6018.33","volume":"33","author":"M Maio","year":"2015","unstructured":"Maio M, Grob J-J, Aamdal S, Bondarenko I, Robert C, Thomas L et al (2015) Five-year survival rates for treatment-naive patients with advanced melanoma who received ipilimumab plus dacarbazine in a phase III trial. J Clin Oncol 33(10):1191\u20131196. https:\/\/doi.org\/10.1200\/JCO.2014.56.6018.33","journal-title":"J Clin Oncol"},{"issue":"5","key":"10180_CR44","doi-asserted-by":"publisher","first-page":"390","DOI":"10.1016\/j.ad.2018.02.008","volume":"109","author":"D Moreno-Ram\u00edrez","year":"2018","unstructured":"Moreno-Ram\u00edrez D, Boada A, Ferr\u00e1ndiz L, Samaniego E, Carretero G, Nagore E, Redondo P, Ortiz-Romero P, Malvehy J, Botella-Estrada R (2018) Lymph\nnode dissection in patients with melanoma and sentinel lymph node metastasis:\nan updated, evidence-based decision algorithm. Actas Dermosifiliogr 109(5):390\u2013398","journal-title":"Actas Dermosifiliogr"},{"issue":"6","key":"10180_CR45","doi-asserted-by":"publisher","first-page":"770","DOI":"10.1002\/jso.23702","volume":"110","author":"BA Byers","year":"2014","unstructured":"Byers BA, Temple-Oberle CF, Hurdle V, McKinnon JG (2014) Treatment of in-transit melanoma with intra-lesional interleukin-2: a systematic review. J Surg Oncol 110(6):770\u2013775","journal-title":"J Surg Oncol"},{"key":"10180_CR46","first-page":"1","volume":"10","author":"F Petrelli","year":"2021","unstructured":"Petrelli F, Ghidini A, Simioni A, Campana LG (2021) Impact of electrochemotherapy in metastatic cutaneous melanoma: a contemporary systematic review and meta-analysis. Acta Oncol 10:1\u201312","journal-title":"Acta Oncol"}],"container-title":["Clinical &amp; Experimental Metastasis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10585-022-10180-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10585-022-10180-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10585-022-10180-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,9,14]],"date-time":"2022-09-14T07:25:25Z","timestamp":1663140325000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10585-022-10180-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,7,22]]},"references-count":46,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2022,10]]}},"alternative-id":["10180"],"URL":"https:\/\/doi.org\/10.1007\/s10585-022-10180-9","relation":{},"ISSN":["0262-0898","1573-7276"],"issn-type":[{"value":"0262-0898","type":"print"},{"value":"1573-7276","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,7,22]]},"assertion":[{"value":"19 November 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 July 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 July 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"F.D.T. is an employee at IGEA. Two authors (A.G.M. and P.D.I) has received funding from IGEA. All other authors declare that they have no potential conflict of interest in relation to the study in this paper.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interest"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Research involving human participants and\/or animals"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}